المؤلفون: Atkinson V., Haydon A., Millward M., Begbie S., Brown M., Markman B., Patterson W., Hill A., Horvath L., Nagrial A., Richardson G., Jackson C., Friedlander M., Parente P., Tran B., Wang L., Chen Y., Tang Z., Huang W., Wu J., Zeng D., Luo L., Solomon B., Desai J., Gan H., Barrow C., Jameson M.

مصطلحات الفهرس: endometrium cancer/di [Diagnosis], endometrium cancer/dt [Drug Therapy], endometrium cancer/et [Etiology], enzyme inhibition, fatigue/si [Side Effect], female, fever/si [Side Effect], gastroesophageal reflux/si [Side Effect], glossodynia/si [Side Effect], hand foot syndrome/si [Side Effect], headache/si [Side Effect], human, hyperkeratosis/si [Side Effect], hypertension/si [Side Effect], hypomagnesemia/si [Side Effect], hypophosphatemia/si [Side Effect], hypotension/si [Side Effect], insomnia/si [Side Effect], intestine obstruction/si [Side Effect], intestine perforation/si [Side Effect], lethargy/si [Side Effect], limb pain/si [Side Effect], major clinical study, male, maximum plasma concentration, maximum tolerated dose, melanoma/di [Diagnosis], melanoma/dt [Drug Therapy], melanoma/et [Etiology], multiple cycle treatment, muscle spasm/si [Side Effect], musculoskeletal chest pain/si [Side Effect], myalgia/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], non small cell lung cancer/di [Diagnosis], non small cell lung cancer/dt [Drug Therapy], non small cell lung cancer/et [Etiology], oncogene N ras, oropharynx pain/si [Side Effect], ovary cancer/di [Diagnosis], ovary cancer/dt [Drug Therapy], ovary cancer/et [Etiology], palmoplantar keratoderma/si [Side Effect], pericardial effusion/si [Side Effect], phase 1 clinical trial, photosensitivity/si [Side Effect], pleura effusion/si [Side Effect], positron emission tomography-computed tomography, priority journal, progression free survival, pruritus/si [Side Effect], QT prolongation/si [Side Effect], rash/si [Side Effect], sepsis/si [Side Effect], side effect/si [Side Effect], skin defect/si [Side Effect], skin hypertrophy/si [Side Effect], solid malignant neoplasm, thrombocytopenia/si [Side Effect], thrush/si [Side Effect], thyroid cancer/di [Diagnosis], thyroid cancer/dt [Drug Therapy], thyroid cancer/et [Etiology], thyroid papillary carcinoma/di [Diagnosis], thyroid papillary carcinoma/dt [Drug Therapy], thyroid papillary carcinoma/et [Etiology], treatment duration, upper abdominal pain/si [Side Effect], upper respiratory tract infection/si [Side Effect], urinary tract infection/si [Side Effect], vomiting/si [Side Effect], xerostomia/si [Side Effect], alanine aminotransferase/ec [Endogenous Compound], B Raf kinase/ec [Endogenous Compound], K ras protein/ec [Endogenous Compound], lifirafenib/ae [Adverse Drug Reaction], lifirafenib/ct [Clinical Trial], lifirafenib/cr [Drug Concentration], lifirafenib/do [Drug Dose], lifirafenib/dt [Drug Therapy], lifirafenib/to [Drug Toxicity], lifirafenib/pd [Pharmacology], dizziness/si [Side Effect], abdominal pain/si [Side Effect], adult, aged, alanine aminotransferase blood level, anemia/si [Side Effect], antineoplastic activity, arthralgia/si [Side Effect], article, backache/si [Side Effect], blood level, blood toxicity/si [Side Effect], body weight disorder/si [Side Effect], body weight loss, brain hemorrhage/si [Side Effect], cancer chemotherapy, cancer patient, cancer radiotherapy, cancer staging, cancer survival, chill/si [Side Effect], cohort analysis, colorectal cancer/di [Diagnosis], colorectal cancer/dt [Drug Therapy], colorectal cancer/et [Etiology], constipation/si [Side Effect], coughing/si [Side Effect], decreased appetite/si [Side Effect], dermatitis/si [Side Effect], diarrhea/si [Side Effect], disease exacerbation/si [Side Effect], drug blood level, drug dose increase, drug half life, drug safety, drug tolerability, dry skin/si [Side Effect], dysgeusia/si [Side Effect], dysphonia/si [Side Effect], dyspnea/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28975
Journal of Clinical Oncology
Click here for full text options
LibKey Link

المؤلفون: Chew C.Y., Saracino A.M., Nikpour M., Mar A.

مصطلحات الفهرس: drug absorption, drug bioavailability, drug contraindication, drug efficacy, drug metabolism, drug safety, erythema annulare centrifugum/si [Side Effect], erythema multiforme/si [Side Effect], eye examination, gastrointestinal symptom/si [Side Effect], giant cell granuloma/dt [Drug Therapy], glioblastoma/dt [Drug Therapy], glucose 6 phosphate dehydrogenase deficiency, granuloma annulare/dt [Drug Therapy], heart protection, heartburn/si [Side Effect], human, hyperpigmentation/si [Side Effect], hypertransaminasemia/si [Side Effect], hypoglycemia/si [Side Effect], immunomodulation, irritability, leukopenia/si [Side Effect], lichen (disease)/dt [Drug Therapy], lichen planus/dt [Drug Therapy], lichen sclerosus et atrophicus/dt [Drug Therapy], liver toxicity/si [Side Effect], lung cancer/dt [Drug Therapy], lupus vulgaris/dt [Drug Therapy], measles like rash/si [Side Effect], melanoma/dt [Drug Therapy], mood change, morphea/dt [Drug Therapy], mucinosis/dt [Drug Therapy], multiple myeloma/dt [Drug Therapy], nausea/si [Side Effect], necrobiosis lipoidica/dt [Drug Therapy], nightmare/si [Side Effect], nonhuman, outcome assessment, pancreas cancer/dt [Drug Therapy], panniculitis/dt [Drug Therapy], patient monitoring, pharmacodynamics, photodermatosis/dt [Drug Therapy], porphyria cutanea tarda/dt [Drug Therapy], practice guideline, pregnancy, prescription, pruritus/si [Side Effect], psoriasis/si [Side Effect], rash/si [Side Effect], retina maculopathy/si [Side Effect], retinopathy/si [Side Effect], review, risk benefit analysis, risk reduction, sarcoma/dt [Drug Therapy], side effect/si [Side Effect], skin contusion/si [Side Effect], skin sarcoidosis/dt [Drug Therapy], smoking, solid malignant neoplasm/dt [Drug Therapy], Stevens Johnson syndrome/si [Side Effect], systemic lupus erythematosus/dt [Drug Therapy], systemic sclerosis/dt [Drug Therapy], toxic epidermal necrolysis/si [Side Effect], treatment response, urticaria/si [Side Effect], vasculitis/dt [Drug Therapy], visual impairment/si [Side Effect], vomiting/si [Side Effect], cyclosporine/it [Drug Interaction], digoxin/it [Drug Interaction], glucose 6 phosphate dehydrogenase/ec [Endogenous Compound], hydroxychloroquine/ae [Adverse Drug Reaction], hydroxychloroquine/it [Drug Interaction], hydroxychloroquine/dt [Drug Therapy], hydroxychloroquine/pk [Pharmacokinetics], hydroxychloroquine/pd [Pharmacology], methotrexate/it [Drug Interaction], follicular mucinosis/dt [Drug Therapy], lichen planopilaris/dt [Drug Therapy], reticular erythematous mucinosis/dt [Drug Therapy], urticarial vasculitis/dt [Drug Therapy], laboratory test, abdominal distension/si [Side Effect], acute generalized exanthematous pustulosis/si [Side Effect], agranulocytosis/si [Side Effect], alopecia/si [Side Effect], alopecia areata/dt [Drug Therapy], anorexia/si [Side Effect], antineoplastic activity, antiphospholipid syndrome/dt [Drug Therapy], antithrombotic activity, aplastic anemia/si [Side Effect], blood toxicity/si [Side Effect], chronic urticaria/dt [Drug Therapy], dermatology, dermatomyositis/dt [Drug Therapy], diarrhea/si [Side Effect], DRESS syndrome/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35375
Australasian Journal of Dermatology
Click here for full text options
LibKey Link

المؤلفون: Lam M., Prenen H., Body A., Segelov E., Lum C.

مصطلحات الفهرس: cross infection, digital rectal examination, epidemiological data, hormone action, immunocompromised patient, infection prevention, intensity modulated radiation therapy, mixed infection, nonhuman, papillomavirus infection, pathophysiology, positron emission tomography-computed tomography, prevalence, radiation injury, review, risk assessment, risk factor, salvage therapy, sexual behavior, sexually transmitted disease, smoking habit, treatment duration, treatment response, trend study, uterine cervix cancer, viral clearance, virus strain, atezolizumab/cb [Drug Combination], atezolizumab/dt [Drug Therapy], avelumab/cb [Drug Combination], avelumab/cm [Drug Comparison], capecitabine/ct [Clinical Trial], capecitabine/dt [Drug Therapy], carboplatin/ct [Clinical Trial], carboplatin/cb [Drug Combination], carboplatin/dt [Drug Therapy], cetuximab/ct [Clinical Trial], cetuximab/cb [Drug Combination], cetuximab/cm [Drug Comparison], cetuximab/dt [Drug Therapy], circulating tumor DNA/ec [Endogenous Compound], cisplatin/ct [Clinical Trial], cisplatin/cb [Drug Combination], cisplatin/cm [Drug Comparison], cisplatin/dt [Drug Therapy], docetaxel/cb [Drug Combination], docetaxel/cm [Drug Comparison], docetaxel/dt [Drug Therapy], durvalumab/dt [Drug Therapy], estrogen, fluorouracil/ae [Adverse Drug Reaction], fluorouracil/ct [Clinical Trial], fluorouracil/cb [Drug Combination], fluorouracil/cm [Drug Comparison], fluorouracil/dt [Drug Therapy], ipilimumab/cb [Drug Combination], ipilimumab/cm [Drug Comparison], ipilimumab/dt [Drug Therapy], mitomycin/ae [Adverse Drug Reaction], mitomycin/cb [Drug Combination], mitomycin/dt [Drug Therapy], nivolumab/ct [Clinical Trial], nivolumab/cb [Drug Combination], nivolumab/cm [Drug Comparison], nivolumab/dt [Drug Therapy], pembrolizumab/ct [Clinical Trial], pembrolizumab/dt [Drug Therapy], Wart virus vaccine, human, adoptive transfer, anus cancer/di [Diagnosis], anus cancer/dt [Drug Therapy], anus cancer/ep [Epidemiology], anus cancer/rt [Radiotherapy], anus cancer/th [Therapy], blood toxicity/si [Side Effect], cancer growth, cancer immunotherapy, cancer incidence, cancer mortality, cancer prognosis, cancer radiotherapy, cancer screening, cancer staging, chemoradiotherapy, colposcopy, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29105
Expert Review of Gastroenterology and Hepatology
LibKey Link

المؤلفون: Atkinson V., Haydon A., Millward M., Begbie S., Brown M., Markman B., Patterson W., Hill A., Horvath L., Nagrial A., Richardson G., Jackson C., Friedlander M., Parente P., Tran B., Wang L., Chen Y., Tang Z., Huang W., Wu J., Zeng D., Luo L., Solomon B., Desai J., Gan H., Barrow C., Jameson M.

مصطلحات الفهرس: endometrium cancer/di [Diagnosis], endometrium cancer/dt [Drug Therapy], endometrium cancer/et [Etiology], enzyme inhibition, fatigue/si [Side Effect], female, fever/si [Side Effect], gastroesophageal reflux/si [Side Effect], glossodynia/si [Side Effect], hand foot syndrome/si [Side Effect], headache/si [Side Effect], human, hyperkeratosis/si [Side Effect], hypertension/si [Side Effect], hypomagnesemia/si [Side Effect], hypophosphatemia/si [Side Effect], hypotension/si [Side Effect], insomnia/si [Side Effect], intestine obstruction/si [Side Effect], intestine perforation/si [Side Effect], lethargy/si [Side Effect], limb pain/si [Side Effect], major clinical study, male, maximum plasma concentration, maximum tolerated dose, melanoma/di [Diagnosis], melanoma/dt [Drug Therapy], melanoma/et [Etiology], multiple cycle treatment, muscle spasm/si [Side Effect], musculoskeletal chest pain/si [Side Effect], myalgia/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], non small cell lung cancer/di [Diagnosis], non small cell lung cancer/dt [Drug Therapy], non small cell lung cancer/et [Etiology], oncogene N ras, oropharynx pain/si [Side Effect], ovary cancer/di [Diagnosis], ovary cancer/dt [Drug Therapy], ovary cancer/et [Etiology], palmoplantar keratoderma/si [Side Effect], pericardial effusion/si [Side Effect], phase 1 clinical trial, photosensitivity/si [Side Effect], pleura effusion/si [Side Effect], positron emission tomography-computed tomography, priority journal, progression free survival, pruritus/si [Side Effect], QT prolongation/si [Side Effect], rash/si [Side Effect], sepsis/si [Side Effect], side effect/si [Side Effect], skin defect/si [Side Effect], skin hypertrophy/si [Side Effect], solid malignant neoplasm, thrombocytopenia/si [Side Effect], thrush/si [Side Effect], thyroid cancer/di [Diagnosis], thyroid cancer/dt [Drug Therapy], thyroid cancer/et [Etiology], thyroid papillary carcinoma/di [Diagnosis], thyroid papillary carcinoma/dt [Drug Therapy], thyroid papillary carcinoma/et [Etiology], treatment duration, upper abdominal pain/si [Side Effect], upper respiratory tract infection/si [Side Effect], urinary tract infection/si [Side Effect], vomiting/si [Side Effect], xerostomia/si [Side Effect], alanine aminotransferase/ec [Endogenous Compound], B Raf kinase/ec [Endogenous Compound], K ras protein/ec [Endogenous Compound], lifirafenib/ae [Adverse Drug Reaction], lifirafenib/ct [Clinical Trial], lifirafenib/cr [Drug Concentration], lifirafenib/do [Drug Dose], lifirafenib/dt [Drug Therapy], lifirafenib/to [Drug Toxicity], lifirafenib/pd [Pharmacology], dizziness/si [Side Effect], abdominal pain/si [Side Effect], adult, aged, alanine aminotransferase blood level, anemia/si [Side Effect], antineoplastic activity, arthralgia/si [Side Effect], article, backache/si [Side Effect], blood level, blood toxicity/si [Side Effect], body weight disorder/si [Side Effect], body weight loss, brain hemorrhage/si [Side Effect], cancer chemotherapy, cancer patient, cancer radiotherapy, cancer staging, cancer survival, chill/si [Side Effect], cohort analysis, colorectal cancer/di [Diagnosis], colorectal cancer/dt [Drug Therapy], colorectal cancer/et [Etiology], constipation/si [Side Effect], coughing/si [Side Effect], decreased appetite/si [Side Effect], dermatitis/si [Side Effect], diarrhea/si [Side Effect], disease exacerbation/si [Side Effect], drug blood level, drug dose increase, drug half life, drug safety, drug tolerability, dry skin/si [Side Effect], dysgeusia/si [Side Effect], dysphonia/si [Side Effect], dyspnea/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28975
Journal of Clinical Oncology
LibKey Link

المؤلفون: Chew C.Y., Saracino A.M., Nikpour M., Mar A.

مصطلحات الفهرس: drug absorption, drug bioavailability, drug contraindication, drug efficacy, drug metabolism, drug safety, erythema annulare centrifugum/si [Side Effect], erythema multiforme/si [Side Effect], eye examination, gastrointestinal symptom/si [Side Effect], giant cell granuloma/dt [Drug Therapy], glioblastoma/dt [Drug Therapy], glucose 6 phosphate dehydrogenase deficiency, granuloma annulare/dt [Drug Therapy], heart protection, heartburn/si [Side Effect], human, hyperpigmentation/si [Side Effect], hypertransaminasemia/si [Side Effect], hypoglycemia/si [Side Effect], immunomodulation, irritability, leukopenia/si [Side Effect], lichen (disease)/dt [Drug Therapy], lichen planus/dt [Drug Therapy], lichen sclerosus et atrophicus/dt [Drug Therapy], liver toxicity/si [Side Effect], lung cancer/dt [Drug Therapy], lupus vulgaris/dt [Drug Therapy], measles like rash/si [Side Effect], melanoma/dt [Drug Therapy], mood change, morphea/dt [Drug Therapy], mucinosis/dt [Drug Therapy], multiple myeloma/dt [Drug Therapy], nausea/si [Side Effect], necrobiosis lipoidica/dt [Drug Therapy], nightmare/si [Side Effect], nonhuman, outcome assessment, pancreas cancer/dt [Drug Therapy], panniculitis/dt [Drug Therapy], patient monitoring, pharmacodynamics, photodermatosis/dt [Drug Therapy], porphyria cutanea tarda/dt [Drug Therapy], practice guideline, pregnancy, prescription, pruritus/si [Side Effect], psoriasis/si [Side Effect], rash/si [Side Effect], retina maculopathy/si [Side Effect], retinopathy/si [Side Effect], review, risk benefit analysis, risk reduction, sarcoma/dt [Drug Therapy], side effect/si [Side Effect], skin contusion/si [Side Effect], skin sarcoidosis/dt [Drug Therapy], smoking, solid malignant neoplasm/dt [Drug Therapy], Stevens Johnson syndrome/si [Side Effect], systemic lupus erythematosus/dt [Drug Therapy], systemic sclerosis/dt [Drug Therapy], toxic epidermal necrolysis/si [Side Effect], treatment response, urticaria/si [Side Effect], vasculitis/dt [Drug Therapy], visual impairment/si [Side Effect], vomiting/si [Side Effect], cyclosporine/it [Drug Interaction], digoxin/it [Drug Interaction], glucose 6 phosphate dehydrogenase/ec [Endogenous Compound], hydroxychloroquine/ae [Adverse Drug Reaction], hydroxychloroquine/it [Drug Interaction], hydroxychloroquine/dt [Drug Therapy], hydroxychloroquine/pk [Pharmacokinetics], hydroxychloroquine/pd [Pharmacology], methotrexate/it [Drug Interaction], follicular mucinosis/dt [Drug Therapy], lichen planopilaris/dt [Drug Therapy], reticular erythematous mucinosis/dt [Drug Therapy], urticarial vasculitis/dt [Drug Therapy], laboratory test, abdominal distension/si [Side Effect], acute generalized exanthematous pustulosis/si [Side Effect], agranulocytosis/si [Side Effect], alopecia/si [Side Effect], alopecia areata/dt [Drug Therapy], anorexia/si [Side Effect], antineoplastic activity, antiphospholipid syndrome/dt [Drug Therapy], antithrombotic activity, aplastic anemia/si [Side Effect], blood toxicity/si [Side Effect], chronic urticaria/dt [Drug Therapy], dermatology, dermatomyositis/dt [Drug Therapy], diarrhea/si [Side Effect], DRESS syndrome/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35375
Australasian Journal of Dermatology
LibKey Link

المؤلفون: Alamgeer M., Lum C.

مصطلحات الفهرس: drug efficacy, drug potentiation, encephalitis/si [Side Effect], fatigue/si [Side Effect], genetic heterogeneity, genomics, hand foot syndrome/si [Side Effect], hedgehog signaling, human, hypertension/si [Side Effect], liquid biopsy, monotherapy, mutational load, nonhuman, Notch signaling, overall survival, pneumonia/si [Side Effect], progression free survival, review, small cell lung cancer/dt [Drug Therapy], small cell lung cancer/rt [Radiotherapy], solid malignant neoplasm/dt [Drug Therapy], adavosertib/ct [Clinical Trial], adavosertib/cb [Drug Combination], adavosertib/dt [Drug Therapy], alisertib/ct [Clinical Trial], alisertib/cb [Drug Combination], alisertib/cm [Drug Comparison], alisertib/dt [Drug Therapy], anlotinib/ae [Adverse Drug Reaction], anlotinib/ct [Clinical Trial], carboplatin/ae [Adverse Drug Reaction], carboplatin/ct [Clinical Trial], carboplatin/cb [Drug Combination], carboplatin/dt [Drug Therapy], cediranib/ct [Clinical Trial], cediranib/cb [Drug Combination], cediranib/dt [Drug Therapy], cisplatin/ct [Clinical Trial], cisplatin/cb [Drug Combination], cisplatin/dt [Drug Therapy], cixutumumab/cb [Drug Combination], cixutumumab/dt [Drug Therapy], crlx101/ct [Clinical Trial], crlx101/cb [Drug Combination], crlx101/dt [Drug Therapy], durvalumab/ct [Clinical Trial], durvalumab/cb [Drug Combination], durvalumab/dt [Drug Therapy], etoposide/ae [Adverse Drug Reaction], etoposide/ct [Clinical Trial], etoposide/cb [Drug Combination], etoposide/dt [Drug Therapy], gemcitabine/ct [Clinical Trial], gemcitabine/cb [Drug Combination], gemcitabine/dt [Drug Therapy], ipilimumab/ae [Adverse Drug Reaction], ipilimumab/ct [Clinical Trial], ipilimumab/cb [Drug Combination], ipilimumab/cm [Drug Comparison], ipilimumab/dt [Drug Therapy], lurbinectedin/ae [Adverse Drug Reaction], lurbinectedin/ct [Clinical Trial], lurbinectedin/dt [Drug Therapy], lurbinectedin/tm [Unexpected Outcome of Drug Treatment], niraparib/ct [Clinical Trial], niraparib/cb [Drug Combination], niraparib/cm [Drug Comparison], niraparib/dt [Drug Therapy], nivolumab/ae [Adverse Drug Reaction], nivolumab/ct [Clinical Trial], nivolumab/cb [Drug Combination], nivolumab/cm [Drug Comparison], nivolumab/dt [Drug Therapy], olaparib/ae [Adverse Drug Reaction], olaparib/ct [Clinical Trial], olaparib/cb [Drug Combination], olaparib/cm [Drug Comparison], olaparib/dt [Drug Therapy], paclitaxel/ct [Clinical Trial], paclitaxel/cb [Drug Combination], paclitaxel/dt [Drug Therapy], placebo, prexasertib/ct [Clinical Trial], prexasertib/cb [Drug Combination], prexasertib/dt [Drug Therapy], rovalpituzumab tesirine/ct [Clinical Trial], rovalpituzumab tesirine/cb [Drug Combination], rovalpituzumab tesirine/cm [Drug Comparison], rovalpituzumab tesirine/dt [Drug Therapy], rucaparib/ct [Clinical Trial], rucaparib/cb [Drug Combination], rucaparib/dt [Drug Therapy], sonidegib/ct [Clinical Trial], sonidegib/cb [Drug Combination], sonidegib/dt [Drug Therapy], sonidegib/tm [Unexpected Outcome of Drug Treatment], taladegib/ct [Clinical Trial], taladegib/cb [Drug Combination], taladegib/dt [Drug Therapy], talazoparib/dt [Drug Therapy], talazoparib/tm [Unexpected Outcome of Drug Treatment], temozolomide/ae [Adverse Drug Reaction], temozolomide/ct [Clinical Trial], temozolomide/cb [Drug Combination], temozolomide/dt [Drug Therapy], topotecan/ct [Clinical Trial], topotecan/cm [Drug Comparison], topotecan/dt [Drug Therapy], unindexed drug, veliparib/ae [Adverse Drug Reaction], veliparib/ct [Clinical Trial], veliparib/cb [Drug Combination], veliparib/cm [Drug Comparison], veliparib/dt [Drug Therapy], vismodegib/dt [Drug Therapy], vismodegib/cb [Drug Combination], anlotinib/cm [Drug Comparison], anlotinib/dt [Drug Therapy], bevacizumab/ct [Clinical Trial], bevacizumab/cb [Drug Combination], bevacizumab/dt [Drug Therapy], adoptive immunotherapy, anorexia/si [Side Effect], blood toxicity/si [Side Effect], bone marrow suppression/si [Side Effect], cancer immunotherapy, cancer resistance, circulating tumor cell, DNA damage response, drug dose escalation, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35889
Cancers
Click here for full text options
LibKey Link

المؤلفون: Alamgeer M., Lum C.

مصطلحات الفهرس: drug efficacy, drug potentiation, encephalitis/si [Side Effect], fatigue/si [Side Effect], genetic heterogeneity, genomics, hand foot syndrome/si [Side Effect], hedgehog signaling, human, hypertension/si [Side Effect], liquid biopsy, monotherapy, mutational load, nonhuman, Notch signaling, overall survival, pneumonia/si [Side Effect], progression free survival, review, small cell lung cancer/dt [Drug Therapy], small cell lung cancer/rt [Radiotherapy], solid malignant neoplasm/dt [Drug Therapy], adavosertib/ct [Clinical Trial], adavosertib/cb [Drug Combination], adavosertib/dt [Drug Therapy], alisertib/ct [Clinical Trial], alisertib/cb [Drug Combination], alisertib/cm [Drug Comparison], alisertib/dt [Drug Therapy], anlotinib/ae [Adverse Drug Reaction], anlotinib/ct [Clinical Trial], carboplatin/ae [Adverse Drug Reaction], carboplatin/ct [Clinical Trial], carboplatin/cb [Drug Combination], carboplatin/dt [Drug Therapy], cediranib/ct [Clinical Trial], cediranib/cb [Drug Combination], cediranib/dt [Drug Therapy], cisplatin/ct [Clinical Trial], cisplatin/cb [Drug Combination], cisplatin/dt [Drug Therapy], cixutumumab/cb [Drug Combination], cixutumumab/dt [Drug Therapy], crlx101/ct [Clinical Trial], crlx101/cb [Drug Combination], crlx101/dt [Drug Therapy], durvalumab/ct [Clinical Trial], durvalumab/cb [Drug Combination], durvalumab/dt [Drug Therapy], etoposide/ae [Adverse Drug Reaction], etoposide/ct [Clinical Trial], etoposide/cb [Drug Combination], etoposide/dt [Drug Therapy], gemcitabine/ct [Clinical Trial], gemcitabine/cb [Drug Combination], gemcitabine/dt [Drug Therapy], ipilimumab/ae [Adverse Drug Reaction], ipilimumab/ct [Clinical Trial], ipilimumab/cb [Drug Combination], ipilimumab/cm [Drug Comparison], ipilimumab/dt [Drug Therapy], lurbinectedin/ae [Adverse Drug Reaction], lurbinectedin/ct [Clinical Trial], lurbinectedin/dt [Drug Therapy], lurbinectedin/tm [Unexpected Outcome of Drug Treatment], niraparib/ct [Clinical Trial], niraparib/cb [Drug Combination], niraparib/cm [Drug Comparison], niraparib/dt [Drug Therapy], nivolumab/ae [Adverse Drug Reaction], nivolumab/ct [Clinical Trial], nivolumab/cb [Drug Combination], nivolumab/cm [Drug Comparison], nivolumab/dt [Drug Therapy], olaparib/ae [Adverse Drug Reaction], olaparib/ct [Clinical Trial], olaparib/cb [Drug Combination], olaparib/cm [Drug Comparison], olaparib/dt [Drug Therapy], paclitaxel/ct [Clinical Trial], paclitaxel/cb [Drug Combination], paclitaxel/dt [Drug Therapy], placebo, prexasertib/ct [Clinical Trial], prexasertib/cb [Drug Combination], prexasertib/dt [Drug Therapy], rovalpituzumab tesirine/ct [Clinical Trial], rovalpituzumab tesirine/cb [Drug Combination], rovalpituzumab tesirine/cm [Drug Comparison], rovalpituzumab tesirine/dt [Drug Therapy], rucaparib/ct [Clinical Trial], rucaparib/cb [Drug Combination], rucaparib/dt [Drug Therapy], sonidegib/ct [Clinical Trial], sonidegib/cb [Drug Combination], sonidegib/dt [Drug Therapy], sonidegib/tm [Unexpected Outcome of Drug Treatment], taladegib/ct [Clinical Trial], taladegib/cb [Drug Combination], taladegib/dt [Drug Therapy], talazoparib/dt [Drug Therapy], talazoparib/tm [Unexpected Outcome of Drug Treatment], temozolomide/ae [Adverse Drug Reaction], temozolomide/ct [Clinical Trial], temozolomide/cb [Drug Combination], temozolomide/dt [Drug Therapy], topotecan/ct [Clinical Trial], topotecan/cm [Drug Comparison], topotecan/dt [Drug Therapy], unindexed drug, veliparib/ae [Adverse Drug Reaction], veliparib/ct [Clinical Trial], veliparib/cb [Drug Combination], veliparib/cm [Drug Comparison], veliparib/dt [Drug Therapy], vismodegib/dt [Drug Therapy], vismodegib/cb [Drug Combination], anlotinib/cm [Drug Comparison], anlotinib/dt [Drug Therapy], bevacizumab/ct [Clinical Trial], bevacizumab/cb [Drug Combination], bevacizumab/dt [Drug Therapy], adoptive immunotherapy, anorexia/si [Side Effect], blood toxicity/si [Side Effect], bone marrow suppression/si [Side Effect], cancer immunotherapy, cancer resistance, circulating tumor cell, DNA damage response, drug dose escalation, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35889
Cancers
LibKey Link

المؤلفون: Abdi E., Begbie S., Clingan P., Ganju V., Beith J., Links M., Goel S., Lewis C.R.

مصطلحات الفهرس: diarrhea/si [Side Effect], disease course, drug dose reduction, drug efficacy, drug safety, drug withdrawal, dyspnea/si [Side Effect], fatigue/si [Side Effect], febrile neutropenia/si [Side Effect], female, follow up, gout/si [Side Effect], heart disease/si [Side Effect], human, leukopenia/si [Side Effect], liver function test, male, metastasis/di [Diagnosis], metastasis/dt [Drug Therapy], motor neuropathy/si [Side Effect], multicenter study, multiple cycle treatment, pleura effusion/si [Side Effect], priority journal, sensory neuropathy/si [Side Effect], side effect/si [Side Effect], single blind procedure, survival time, thrombocytopenia/si [Side Effect], treatment duration, treatment outcome, weight reduction, anthracycline/dt [Drug Therapy], antiemetic agent, dexamethasone/po [Oral Drug Administration], docetaxel/ae [Adverse Drug Reaction], docetaxel/ct [Clinical Trial], docetaxel/cb [Drug Combination], docetaxel/do [Drug Dose], docetaxel/dt [Drug Therapy], docetaxel/iv [Intravenous Drug Administration], gemcitabine/ae [Adverse Drug Reaction], gemcitabine/ct [Clinical Trial], gemcitabine/cb [Drug Combination], gemcitabine/do [Drug Dose], gemcitabine/dt [Drug Therapy], gemcitabine/iv [Intravenous Drug Administration], clinical trial, nausea/si [Side Effect], neurotoxicity/si [Side Effect], neutropenia/si [Side Effect], phase 2 clinical trial, adult, aged, anemia/si [Side Effect], article, blood toxicity/si [Side Effect], bone marrow suppression/si [Side Effect], breast cancer/di [Diagnosis], breast cancer/dt [Drug Therapy], breast cancer/rt [Radiotherapy], breast cancer/su [Surgery], cancer localization, chemotherapy induced emesis/si [Side Effect], clinical article, controlled clinical trial, controlled study, deep vein thrombosis/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/31323
Click here for full text options
LibKey Link

المؤلفون: Toner G.C., Brettell M., Strickland A., Zalcberg J., Richardson G., Scarlett J., Briggs P., Prince H.M., Millward M.J., Rischin D., Blakey D., Francis P., Gates P., Chapple P., Quinn M., Juneja S., Wolf M., Januszewicz E.H., Seymour J.F.

مصطلحات الفهرس: article, bleeding/si [Side Effect], blood toxicity/si [Side Effect], breast carcinoma/dt [Drug Therapy], cancer combination chemotherapy, clinical article, clinical trial, dose response, enterocolitis/si [Side Effect], gastrointestinal toxicity/si [Side Effect], human, kidney tubule acidosis/si [Side Effect], metastasis/dt [Drug Therapy], mucosa inflammation/si [Side Effect], phase 1 clinical trial, priority journal, subcutaneous drug administration, cyclophosphamide, ifosfamide/ae [Adverse Drug Reaction], ifosfamide/ct [Clinical Trial], ifosfamide/cb [Drug Combination], ifosfamide/do [Drug Dose], ifosfamide/dt [Drug Therapy], ifosfamide/pd [Pharmacology], mesna, paclitaxel/ae [Adverse Drug Reaction], paclitaxel/ct [Clinical Trial], paclitaxel/cb [Drug Combination], paclitaxel/do [Drug Dose], paclitaxel/dt [Drug Therapy], paclitaxel/pd [Pharmacology], recombinant granulocyte colony stimulating factor/ct [Clinical Trial], recombinant granulocyte colony stimulating factor/cb [Drug Combination], thiotepa/ae [Adverse Drug Reaction], thiotepa/ct [Clinical Trial], thiotepa/cb [Drug Combination], thiotepa/do [Drug Dose], thiotepa/dt [Drug Therapy], thiotepa/pd [Pharmacology], neurotoxicity/si [Side Effect], adult, advanced cancer, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/33536
Click here for full text options
LibKey Link

المؤلفون: Boyer M.J., Zalcberg J., Olver I.N., Millward M.J., Richardson G., McKeage M.J.

مصطلحات الفهرس: lung small cell cancer/dt [Drug Therapy], male, neurotoxicity/si [Side Effect], neutropenia/di [Diagnosis], neutropenia/si [Side Effect], oral drug administration, phase 1 clinical trial, priority journal, thorax radiography, etoposide/ae [Adverse Drug Reaction], etoposide/ct [Clinical Trial], etoposide/ad [Drug Administration], etoposide/cb [Drug Combination], etoposide/do [Drug Dose], etoposide/dt [Drug Therapy], etoposide/pr [Pharmaceutics], paclitaxel/ae [Adverse Drug Reaction], paclitaxel/ct [Clinical Trial], paclitaxel/ad [Drug Administration], paclitaxel/cb [Drug Combination], paclitaxel/do [Drug Dose], paclitaxel/dt [Drug Therapy], clinical article, adult, aged, article, blood cell count, blood toxicity/di [Diagnosis], cancer survival, blood toxicity/si [Side Effect], clinical trial, computer assisted tomography, drug safety, female, human, hypersensitivity/si [Side Effect], leukopenia/di [Diagnosis], leukopenia/si [Side Effect], lung non small cell cancer/di [Diagnosis], lung non small cell cancer/dt [Drug Therapy], lung small cell cancer/di [Diagnosis], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/33822
Click here for full text options
LibKey Link